•$Axsome Therapeutics (AXSM.US)$+33.8% (announces FDA approval of AUVELITY the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults)
•$SpringWorks Therapeutics (SWTX.US)$+4.9% (late-breaking oral presentation of phase 3 DeFi data at the European Society for Medical Oncology Congress 2022)
•$Agios Pharmaceuticals (AGIO.US)$+3.1% (Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND (mitapivat) for Adults with Pyruvate Kinase Deficiency)
•$Bed Bath & Beyond Inc (BBBY.US)$-42.7% (Ryan Cohen completes sale ofBBBYstake; also hires law firm to help address debt load according to Bloomberg Law)
102984910 : Why is EXK dropping so much?